Efficacy and safety of zapnometinib in hospitalised adult patients with COVID-19 (RESPIRE): a randomised, double-blind, placebo-controlled, multicentre, proof-of-concept, phase 2 trialResearch in context

Efficacy and safety of zapnometinib in hospitalised adult patients with COVID-19 (RESPIRE): a randomised, double-blind, placebo-controlled, multicentre, proof-of-concept, phase 2 trialResearch in context

Summary: Background: Zapnometinib is an oral, non-ATP-competitive, small-molecule inhibitor of MEK1/MEK2 with immunomodulatory and antiviral properties. We aimed to investigate the safety and efficacy of zapnometinib in patients with COVID-19. Methods: In this randomised, double-blind, placebo-cont...

Full description

Bibliographic Details
Main Authors: Gernot Rohde, Stephan Stenglein, Hans Prozesky, Ganesh Manudhane, Oana Sandulescu, Martin Bauer, Tim Overend, Winfried Koch, Dennis Neuschwander, Oliver Planz, Antoni Torres, Martin Witzenrath
Format: Article
Language:English
Published: Elsevier 2023-11-01
Series:EClinicalMedicine
Subjects:
COVID-19
Anti-viral
Immunomodulator
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537023004145

Internet

http://www.sciencedirect.com/science/article/pii/S2589537023004145

Similar Items